Archive for August 28, 2008

The AIDS Epidemic — A Progress Report from Mexico City

N Engl J of Medicine August 28, 2008  V.359  N.9  p.885-887

Robert Steinbrook, M.D.



August 28, 2008 at 5:24 pm Leave a comment

An HIV Vaccine — Challenges and Prospects

N Engl J of Medicine  August 28, 2008  V.359  N.9  p.888-890


Margaret I. Johnston, Ph.D., and Anthony S. Fauci, M.D.



August 28, 2008 at 5:22 pm Leave a comment

Chronic Hepatitis C Virus Genotype 6 Infection: Response to Pegylated Interferon and Ribavirin

Journal of Infectious Diseases  15 September 2008  V.198  N.6  p.808–812

James Fung, Ching-Lung Lai, Ivan Hung, John Young, Charles Cheng, Danny Wong, and Man-Fung Yuen

Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, China

Background.  To date, no study has evaluated pegylated interferon for the treatment of chronic infection with hepatitis C virus (HCV) genotype 6. We aimed to determine the efficacy of pegylated interferon plus ribavirin for treating infection with genotype 6 versus genotype 1.

Methods.  Forty-two patients chronically infected with HCV (for genotype 1, n=21 ; for genotype 6, n=20  ) were treated with pegylated interferon a-2a (n=20) or a-2b (n=22) combined with oral ribavirin for 48 weeks.

Results.  There was no difference between genotypes 1 and 6 in the rates of early virological response (76% vs. 81%; P>.05) and end-of-treatment response (71% vs. 81%; P>.05). Patients infected with genotype 6 had a higher rate of sustained virological response (SVR) than did patients infected with genotype 1 (86% vs. 52%; P=.019). The overall adverse-effects profile was similar in both genotype groups. There was no significant difference in the rate of SVR between patients receiving pegylated interferon a-2a and those receiving a-2b. Multivariate analysis showed that genotype was the only significant factor associated with SVR (P=-039).

Conclusions.  Treatment with pegylated interferon and ribavirin for 48 weeks resulted in a significantly higher rate of SVR in patients infected with genotype 6 than in those infected with genotype 1. Further studies are required to determine whether lower dosages and 24 weeks of therapy may be sufficient for the treatment of genotype 6 infection.


August 28, 2008 at 5:20 pm Leave a comment


August 2008
« Jul   Sep »

Posts by Month

Posts by Category